R&D : Projects

From its platform, Vaxinano develops as a leader:

• An anti-parasitic vaccine against fatal, chronic and congenital toxoplasmosis for which there is currently no treatment or vaccine for humans.
• Immunotherapeutic treatment to cure leishmaniasis.

This vaccine platform is also used in collaboration to prevent against influenza and Covid-19. Our nasally administered nanoparticle vaccine candidates have been shown to protect against both infection and transmission of these viruses.